iCareDx Announces Appointment Of Advisory Board
16.5.2016 23:48 | Business Wire
iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced the formation of an Advisory Board, comprised of renowned scientists, clinicians and business leaders in the areas of oncology and diagnostics. The Advisory Board’s role will be to provide valuable scientific, clinical and business insights, along with strategic guidance in decision-making, as the Company seeks to advance its blood-based screening tests for early detection of colorectal cancer as well as for early detection in pan-oncology.
“We are honored to welcome such outstanding authorities in their respective areas to our advisory board to support the development of iCareDx's early detection screening technologies,” said Dr. Bernard Peperstraete, the Chief Executive Officer of iCareDx. “In forming the company’s inaugural Advisory Board, we are seeking to further position iCareDx to successfully pursue a highly accurate and cost-effective approach for early cancer detection, and to ultimately help reduce cancer deaths.”
Over the past years, the design of iCareDx's molecular detection technologies was led by Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine. Dr. Barany is a prolific inventor with 52 issued US patents, which are foundational inventions in molecular diagnostics and next generation sequencing, and include the ligase chain reaction (LCR), the ligase detection reaction (LDR), and the Universal DNA array. “We have assembled this team of thought leaders to guide our efforts in advancing our platform for blood-based early cancer detection,” said Dr. Francis Barany. “Our scalable, low-cost cancer detection platforms are designed to vastly improve cancer care, ultimately throughout the world.”
Composition of iCareDx's Advisory Board:
- Mr. Haywood Cochrane. Previously, CEO at CHD Meridian Corp (now part of Walgreens), at Allied Clinical Labs and at Take Care Employer Solutions; EVP, CFO and Treasurer at LabCorp, COO at Biomedical Reference Labs, SVP North-America Diagnostics and COO at Roche Biomedical labs; Director at Tripath Imaging, American Esoteric Labs, Sonus Corp., Ameripath, Unilab Corp.
- Dr. Paolo Fortina. Professor of Cancer Biology and Medical Oncology at the Sidney Kimmel Medical College, Director of the NCI-designated Cancer Genomics Laboratory at the Sidney Kimmel Cancer Center, Thomas Jefferson University.
- Dr. David Gelfand. Previously, Vice President, Discovery Research Division and Director for the Program in Core Research at Roche Molecular Systems, CSO of WaferGen BioSystems, and a consultant at the Centre National de Génotypage in France, inventor of the real-time PCR (“TaqMan”) technology and many thermostable DNA Polymerases and Reverse Transcriptases.
- Dr. Larry J. Kricka. Professor of Pathology & Laboratory Medicine at the University of Pennsylvania Director of the General Chemistry and Endocrinology Laboratory at the Hospital of the University of Pennsylvania.
- Dr. Christopher Mason. Associate Professor Computational Genomics at Weill Cornell Medicine, with appointments at Department of Physiology and Biophysics, Institute for Computational Biomedicine, Meyer Cancer Center, Feil Family Brain and Mind Research Institute. WorldQuant Foundation Research Scholar. Affiliate Fellow of Genomics, Ethics, and Law, ISP, Yale Law School.
- Dr. Kenneth Offit. Chief of Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center, Member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, Professor of Medicine and Public Health at the Weill Cornell Medicine.
- Dr. Mark Pochapin. Sholtz/Leeds Professor, Director of Gastroenterology, Professor of Medicine at NYU Langone Medical Center. Advanced gastrointestinal endoscopy, and the prevention, early detection, and treatment of gastrointestinal cancers.
About iCareDx Inc.
iCareDx is a biotechnology company focused on developing technologies for blood-based early detection of cancer. iCareDx's technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is iCareDx’s mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.
Chief Executive Officer
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30 | Pressemelding
The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04 | Pressemelding
Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57 | Pressemelding
Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08 | Pressemelding
On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00 | Pressemelding
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom